parthenolide,
parthenolide, (1aR-(1aR*,4E,7aS*,10aS*,10bR*))-isomer,
parthenolide,
20554-84-1,
(-)-Parthenolide,
MFCD00134592,
CHEBI:7939,
Parthenolide, Tanacetum parthenium,
4,5-alpha-Epoxy-6-beta-hydroxygermacra-1(10),11(13)-dien-12-oic acid gamma-lactone,
partenolide,
C15H20O3,
29552-41-8,
Oxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one, 2,3,6,7,7a,8,10a,10b-octahydro-1a,5-dimethyl-8-methylene-, (1aR,4E,7aS,10aS,10bR)-,
Prestwick2_000550,
Prestwick3_000550,
Epitope ID:115014,
SCHEMBL8220,
BSPBio_000599,
BSPBio_001308,
MLS002153872,
BPBio1_000659,
CHEMBL465158,
SCHEMBL13367522,
BCBcMAP01_000041,
Parthenolide, >=98% (HPLC),
HMS1361B10,
HMS1569N21,
HMS1791B10,
HMS1989B10,
HMS2096N21,
HMS3402B10,
HMS3713N21,
BCP10404,
HY-N0141,
ZINC4492886,
AKOS016010226,
CCG-208244,
CS-1919,
IDI1_033778,
NCGC00163415-01,
AJ-51217,
AS-17479,
SMR001233226,
AB0019832,
AB00513860,
ST24048874,
V0355,
X-1866,
552P418,
Q-100253,
Parthenolide, United States Pharmacopeia (USP) Reference Standard,
(1aR,4E,7aS,10aS,10bR)-1a,5-dimethyl-8-methylidene-2,3,6,7,7a,8,10a,10b-octahydrooxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one,
(3aS,10R,11R,11aS,6E)-3-Methylene-6,10-dimethyl-10,11-epoxy-1-oxa-2,3,3a,4,5,8,9,10,11,11a-decahydro-1H-cyclopentacyclodecene-2-one,
D0M4KE,
UNII-2RDB26I5ZB,
ACN-035673,
C15-H20-O3,
CID7251185,
NSC 157035,
C002669,
4,5-Epoxy-germacra-1(10)E,11(13)-dien-12,6?-olide,
parthenolide, (1aR-(1aR*,4E,7aS*,10aS*,10bR*))-isomer,
Parthenolide, 98%, from Chrysanthemum morifolium - 100MG 100mg,
4,5alpha-epoxy-6beta-hydroxy-germacra-1(10),11(13)-dien-12-oic acid gamma-lactone,
4,5alpha-Epoxy-6beta-hydroxygermacra-1(10),11(13)-dien-12-oic Acid gamma-Lactone,
Germacra-1(10),11(13)-dien-12-oic acid, 4,5.alpha.-epoxy-6.beta.-hydroxy-, .gamma.-lactone,
Oxireno[9,10]cyclodeca[1,2-b]furan-9(1aH)-one, 2,3,6,7,7a,8,10a,10b-octahydro-1a,5-dimethyl-8-methylene-, [1aR-(1aR*,4E,7aS*,10aS*,10bR*)]-,